Cytogenetic prognostication within medulloblastoma subgroups

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 886-896

  Shih, David J H ^a,b   Northcott, Paul A ^f   Remke, Marc ^a,b   Korshunov, Andrey ^f   Ramaswamy, Vijay ^a,b   Kool, Marcel ^f   Luu, Betty ^a   Yao, Yuan ^a,b   Wang, Xin ^a,b   Dubuc, Adrian M ^a,b   Garzia, Livia ^a   Peacock, John ^a,b   Mack, Stephen C ^a,b   Wu, Xiaochong ^a   Rolider, Adi ^a   Morrissy, A Sorana ^a   Cavalli, Florence M G ^a   Jones, David T W ^f   Zitterbart, Karel ^j,k   Faria, Claudia C ^a,au   Schüller, Ulrich ^h   Kren, Leos ^k   Kumabe, Toshihiro ^l   Tominaga, Teiji ^l   Ra, Young Shin ^m   Garami, Miklós ^p   Hauser, Peter ^p   Chan, Jennifer A ^d   Robinson, Shenandoah ^r   Bognár, László ^q   Klekner, Almos ^q   Saad, Ali G ^t   Liau, Linda M ^u   Albrecht, Steffen ^e   Fontebasso, Adam ^e   Cinalli, Giuseppe ^y   De Antonellis, Pasqualino ^z   Zollo, Massimo ^z,aa   Cooper, Michael K ^ac   Thompson, Reid C ^ac   Bailey, Simon ^ae   Lindsey, Janet C ^ae   Di Rocco, Concezio ^ab   Massimi, Luca ^ab   Michiels, Erna M C ^af   Scherer, Stephen W ^a   Phillips, Joanna J ^v   Gupta, Nalin ^v   Fan, Xing ^ag   Muraszko, Karin M ^ag   Vibhakar, Rajeev ^ah   Eberhart, Charles G ^ai   Fouladi, Maryam ^aj   Lach, Boleslaw ^c   Jung, Shin ^o   Wechsler Reya, Robert J ^w   Fèvre Montange, Michelle ^ak   Jouvet, Anne ^ak   Jabado, Nada ^e   Pollack, Ian F ^an   Weiss, William A ^v   Lee, Ji Yeoun ⁿ   Cho, Byung Kyu ⁿ   Kim, Seung Ki ⁿ   Wang, Kyu Chang ⁿ   Leonard, Jeffrey R ^ao   Rubin, Joshua B ^ao   De Torres, Carmen ^ap   Lavarino, Cinzia ^ap   Mora, Jaume ^ap   Cho, Yoon Jae ^x   Tabori, Uri ^a   Olson, James M ^aq   Gajjar, Amar ^ad   Packer, Roger J ^ar   Rutkowski, Stefan ⁱ   Pomeroy, Scott L ^s   French, Pim J ^af   Kloosterhof, Nanne K ^af   Kros, Johan M ^af   Van Meir, Erwin G ^as   Clifford, Steven C ^ae   Bourdeaut, Franck ^al   Delattre, Olivier ^al   Doz, François F ^al,am   Hawkins, Cynthia E ^a   Malkin, David ^a   Grajkowska, Wieslawa A ^at   Perek Polnik, Marta ^at   Bouffet, Eric ^a   Rutka, James T ^a   Pfister, Stefan M ^f,g   Taylor, Michael D ^a,b   more..

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^j MASARYK UNIVERSITY   (Czech Republic)

^k UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^l TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m University of Ulsan   (South Korea)

ⁿ Seoul National University Children's Hospital   (South Korea)

^o Chonnam National University Research Institute of Medical Sciences   (South Korea)

^p SEMMELWEIS UNIVERSITY   (Hungary)

^q UNIVERSITY OF DEBRECEN   (Hungary)

^r BOSTON CHILDREN S HOSPITAL   (United States)

^s HARVARD MEDICAL SCHOOL   (United States)

^t UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v UNIVERSITY OF CALIFORNIA   (United States)

^w BURNHAM INSTITUTE   (United States)

^x STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^y SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^z UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^aa CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^ab CATHOLIC UNIVERSITY   (Italy)

^ac VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^ad ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^ae NEWCASTLE UNIVERSITY   (United Kingdom)

^af ERASMUS MEDICAL CENTER   (Netherlands)

^ag UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^ah UNIVERSITY OF COLORADO   (United States)

^ai JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^aj UNIVERSITY OF CINCINNATI   (United States)

^ak UNIVERSITÉ DE LYON   (France)

^al INSTITUT CURIE   (France)

^am UNIVERSITÉ PARIS DESCARTES   (France)

^an UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^ao ST LOUIS CHILDREN S HOSPITAL   (United States)

^ap HOSPITAL SANT JOAN DE DÉU   (Spain)

^aq USA   (United States)

^ar CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^as EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^at CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^au HOSPITAL DE SANTA MARIA   (Portugal)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; TRANSCRIPTION FACTOR GLI2; TUMOR MARKER; GLI2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; SHH PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CHROMOSOME 11; CHROMOSOME 14; CHROMOSOME 17P; CHROMOSOME 17Q; CYTOGENETICS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC MARKER; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MEDULLOBLASTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE MICROARRAY; ADOLESCENT; CHILD; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INFANT; MALE; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYTOGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MEDULLOBLASTOMA; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MYC; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; WNT PROTEINS; YOUNG ADULT;

EID: 84899684426     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.9539     Document Type: Article

References (64)

1. Gajjar A, Chintagumpala M, Ashley D, et al: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 7:813-820, 2006 (Pubitemid 44464063)
2. Northcott PA, Korshunov A, Pfister SM, et al: The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 8:340-351, 2012
3. Lannering B, Rutkowski S, Doz F, et al: Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: Results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187-3193, 2012
4. Edelstein K, Spiegler BJ, Fung S, et al: Early aging in adult survivors of childhood medulloblastoma: Long-term neurocognitive, functional, and physical outcomes. Neuro Oncol 13:536-545, 2011
5. Palmer SL, Hassall T, Evankovich K, et al: Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma. Neuro Oncol 12:1311-1317, 2010
6. Lafay-Cousin L, Bouffet E, Hawkins C, et al: Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol 16:21-28, 2009
7. Remke M, Hielscher T, Korshunov A, et al: FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 29:3852-3861, 2011
8. Remke M, Hielscher T, Northcott PA, et al: Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29:2717-2723, 2011
9. Dubuc AM, Northcott PA, Mack S, et al: The genetics of pediatric brain tumors. Curr Neurol Neurosci Rep 10:215-223, 2010
10. Castelo-Branco P, Choufani S, Mack S, et al: Methylation of the TERT promoter and risk stratification of childhood brain tumours: An integrative genomic and molecular study. Lancet Oncol 14:534-542, 2013
11. Northcott PA, Jones DT, Kool M, et al: Medulloblastomics: The end of the beginning. Nat Rev Cancer 12:818-834, 2012
12. Pfister SM, Korshunov A, Kool M, et al: Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 120:553-566, 2010
13. Ramaswamy V, Northcott PA, Taylor MD: FISH and chips: The recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 204:577-588, 2011
14. Northcott PA, Rutka JT, Taylor MD: Genomics of medulloblastoma: From Giemsa-banding to next-generation sequencing in 20 years. Neurosurg Focus 28:E6, 2010
15. Ellison DW, Onilude OE, Lindsey JC, et al: Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 23:7951-7957, 2005 (Pubitemid 46657395)
16. Thompson MC, Fuller C, Hogg TL, et al: Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924-1931, 2006 (Pubitemid 46638992)
17. Rausch T, Jones DT, Zapatka M, et al: Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148:59-71, 2012
18. Pfaff E, Remke M, Sturm D, et al: TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28:5188-5196, 2010
19. Tabori U, Baskin B, Shago M, et al: Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28:1345-1350, 2010
20. Hernan R, Fasheh R, Calabrese C, et al: ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63:140-148, 2003 (Pubitemid 36070432)
21. Gilbertson RJ, Perry RH, Kelly PJ, et al: Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57:3272-3280, 1997 (Pubitemid 27351746)
22. Gilbertson RJ, Pearson AD, Perry RH, et al: Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 71:473-477, 1995
23. Eberhart CG, Kratz J, Wang Y, et al: Histopathological and molecular prognostic markers in medulloblastoma: C-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63:441-449, 2004 (Pubitemid 38669665)
24. Grotzer MA, Janss AJ, Phillips PC, et al: Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212:196-199, 2000 (Pubitemid 30650554)
25. Segal RA, Goumnerova LC, Kwon YK, et al: Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91:12867-12871, 1994
26. McCabe MG, Bäcklund LM, Leong HS, et al: Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro Oncol 13:376-383, 2011
27. Lo KC, Ma C, Bundy BN, et al: Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res 13:7022-7028, 2007 (Pubitemid 350276883)
28. Northcott PA, Shih DJ, Peacock J, et al: Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488:49-56, 2012
29. Northcott PA, Nakahara Y, Wu X, et al: Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41:465-472, 2009
30. Northcott PA, Hielscher T, Dubuc A, et al: Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122:231-240, 2011
31. Pfister S, Remke M, Benner A, et al: Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 27:1627-1636, 2009
32. Kool M, Korshunov A, Remke M, et al: Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol 123:473-484, 2012
33. Clifford SC, O'Toole K, Ellison DW: Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: Requirements for the validation of potential prognostic biomarkers. Cell Cycle 8:787, 2009
34. Clifford SC, Lusher ME, Lindsey JC, et al: Wnt/wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666-2670, 2006
35. Korshunov A, Remke M, Werft W, et al: Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054-3060, 2010
36. Batra SK, McLendon RE, Koo JS, et al: Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol 24:39-45, 1995
37. Park AK, Lee SJ, Phi JH, et al: Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation. Neuro Oncol 14:203-214, 2012
38. Lamont JM, McManamy CS, Pearson AD, et al: Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10:5482-5493, 2004 (Pubitemid 39100486)
39. Gilbertson R, Wickramasinghe C, Hernan R, et al: Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85:705-712, 2001 (Pubitemid 32929469)
40. Mendrzyk F, Radlwimmer B, Joos S, et al: Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 23:8853-8862, 2005 (Pubitemid 46211532)
41. Pan E, Pellarin M, Holmes E, et al: Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 11:4733-4740, 2005 (Pubitemid 41557192)
42. Aldosari N, Bigner SH, Burger PC, et al: MYCC and MYCN oncogene amplification in medulloblastoma: A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126:540-544, 2002 (Pubitemid 34477948)
43. Ellison DW, Kocak M, Dalton J, et al: Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 29:1400-1407, 2011
44. Ryan SL, Schwalbe EC, Cole M, et al: MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 123:501-513, 2012
45. Scheurlen WG, Schwabe GC, Joos S, et al: Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 16:2478-2485, 1998 (Pubitemid 28309044)
46. Bien-Willner GA, López-Terrada D, Bhattacharjee MB, et al: Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement. Neuro Oncol 14:831-840, 2012
47. Adamson DC, Shi Q, Wortham M, et al: OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res 70:181-191, 2010
48. Korshunov A, Remke M, Kool M, et al: Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol 123:515-527, 2012
49. Schwalbe EC, Williamson D, Lindsey JC, et al: DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 125:359-371, 2013
50. Northcott PA, Dubuc AM, Pfister S, et al: Molecular subgroups of medulloblastoma. Expert Rev Neurother 12:871-884, 2012
51. Dubuc AM, Morrissy AS, Kloosterhof NK, et al: Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathol 123:485-499, 2012
52. Taylor MD, Northcott PA, Korshunov A, et al: Molecular subgroups of medulloblastoma: The current consensus. Acta Neuropathol 123:465-472, 2012
53. Northcott PA, Korshunov A, Witt H, et al: Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408-1414, 2011
54. Jones DT, Jäger N, Kool M, et al: Dissecting the genomic complexity underlying medulloblastoma. Nature 488:100-105, 2012
55. Kool M, Koster J, Bunt J, et al: Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088, 2008
56. Parsons DW, Li M, Zhang X, et al: The genetic landscape of the childhood cancer medulloblastoma. Science 331:435-439, 2011
57. Robinson G, Parker M, Kranenburg TA, et al: Novel mutations target distinct subgroups of medulloblastoma. Nature 488:43-48, 2012
58. Schwalbe EC, Lindsey JC, Straughton D, et al: Rapid diagnosis of medulloblastoma molecular subgroups. Clin Cancer Res 17:1883-1894, 2011
59. Ellison DW, Dalton J, Kocak M, et al: Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381-396, 2011
60. Gibson P, Tong Y, Robinson G, et al: Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095-1099, 2010
61. Northcott PA, Shih DJ, Remke M, et al: Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 123:615-626, 2012
62. Pugh TJ, Weeraratne SD, Archer TC, et al: Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488:106-110, 2012
63. Cho YJ, Tsherniak A, Tamayo P, et al: Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 29:1424-1430, 2011
64. Bourdeaut F, Grison C, Maurage CA, et al: MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genet 206:124-129, 2013